A mid-size, top 5 European pharmaceutical company engaged PRA in a global Phase III study in 20 countries on patients with advanced breast cancer previously treated with or resistant to airmaximus an anthracycline and who are taxane resistant. By identifying optimal sites in in Russia, Ukraine, Belarus, and Estonia, PRA recruited 318 patients at 25 sites, compared to 450+ patients at 150 sites in Rest of World (ROW).
Our in-house oncology and hematology experts make the complex, simple. Our
ECG Assessments During the Development of Oncology Compounds
Single-center oncology studies performed by dedicated PRA staff, combined with the High Precision QT approach of iCardiac, generates conclusive ECG…